Posted by SLS on March 25, 2005, at 5:06:42
In reply to Pharmacogenomics making its mark in drug trials, posted by jrbecker on March 23, 2005, at 18:04:42
> a commerical drug company is pioneering the use of genetic testing to identify a sub-sample of depressive sufferers who might respond to the antidepressant vilazodone, a 5-HT1a partial agonist. you might recall that 5-HT1a partial agonists have been shown to have limited efficacy in past trials, however, it is thought that this drug class might be useful for certain types of depression [most likely those with atypical-features]...
I am very, very angry that the FDA said no to gepirone. Very. It was my hopes to try it simply because it was different from everything else. It did demonstrated efficacy, but not enough in the general population of depressives that were included in the trials. It's as if no one thought to give a drug a chance to show itself useful in subpopulations or to use the drug as a potentiator of other drugs much the way the newer anticonvulsants have been developed specifically as adjuncts to the major AEDs. The drug company of gepirone could have chosen to continue pursuing its approval. They wimped out.
- Scott
poster:SLS
thread:474727
URL: http://www.dr-bob.org/babble/20050322/msgs/475291.html